The White House has announced a plan by the Consumer Financial Protection Bureau (CFPB) to exclude medical debt from credit reports, impacting millions in the U.S. with unpaid medical bills. Experts support this move but suggest additional steps to reduce medical debt, including ending extreme […]
The Illusions of the U.S. Pharmaceutical Industry: Misdirection in Drug Pricing, Innovation, and Regulation
The U.S. biopharmaceutical industry uses subtle illusion techniques similar to magicians to distract Americans from truths about drug pricing, innovation, and regulation. These illusions include the assumption that reducing drug prices would harm research and innovation, which in reality it […]
FDA Flags Manufacturing Shortfalls at Novo Nordisk’s North Carolina Plant, Impact on Drug Supply Uncertain
Novo Nordisk's shares have dropped after the FDA reported manufacturing deficiencies at the company's Clayton, North Carolina plant, which produces vital ingredient ingredients like semaglutide. From July 6 to 13, 2023, the FDA inspected the plant and criticized Novo for quality control lapses, […]
Biopharmaceutical Market Capitalization Rises in Q2 2023: Eli Lilly Takes the Lead
The market capitalization of the top 20 biopharmaceutical companies rose by 2.3% to $3.56tn in Q2 2023. Eli Lilly saw a 36.1% increase, making it the leading company in market capitalization, boosted by its diabetes drug Mounjaro and anticipated approval for its use in obesity treatment. […]
U.S. FDA and Pharma Manufacturers Making Progress in Resolving Nationwide Cancer Drug Shortage
The U.S. FDA and pharma manufacturers are progressing in addressing the nationwide shortage of cancer drugs, with the supply of chemotherapy cisplatin nearing pre-shortage levels. Awareness of this shortage has much improved the collection of carboplatin as well. The FDA and pharma manufacturers […]
Alexion Pharmaceuticals Nears $125M Settlement in Class Action Lawsuit Over Alleged Unethical Sales Practices
A 2016 class action lawsuit against pharmaceutical company Alexion, which claimed that the company's unethical sales practices led to a decline in its stock price, might conclude after both parties proposed a $125 million settlement. The lawsuit represented shareholders who bought stocks between […]
Adapting to Challenges and Opportunities: Medical Device Makers in a Tightening Economy
In today's tightening economy, medical device makers face more hurdles with the dwindling post-COVID-19 investment boom and a selective investment approach in healthcare. A fall in funding for digital health startups and slimming operating margins have painted a challenging picture. However, experts […]
AI-Enhanced Testing: Transforming the Landscape of Software Quality Assurance
Traditional test automation has limitations in replicating real-world user behavior and interactivity, which results in a need for an intelligent, dynamic approach to software testing. The leverage of AI in test automation presents a solution to this problem. AI-powered test automation faces […]
Medicare Price Negotiations for Drugs Begin in 2026: Eliquis Among Most Impacted
The Centers for Medicare & Medicaid Services (CMS) has disclosed a list of the initial ten drugs that will undergo Medicare price negotiations under the Inflation Reduction Act (IRA) starting from 2026, with the impact expected to be modest initially but gradually growing as more drugs are added […]
Healthcare Sector Experiences Fluctuating Fund Flows
Top 10 Things You Need to Know: Healthcare is often seen as a defensive sector due to its constant demand and some insulation from the economy. Despite this, the sector is down nearly 2% for the year, while the S&P 500 index has gained over 17%. The latest week saw investors pull a […]
Shortening Mental Health Treatment Waiting Times Could Save NHS Millions and Improve Patient Outcomes
What You Need to Know: Shortening treatment and waiting times for mental health conditions from 12 months to three could lead to financial savings for the NHS and improve treatment outcomes. The study, conducted by ieso Digital Health Ltd in partnership with Dorset HealthCare University NHS […]
Novo Nordisk’s Obesity Drugs Reshape Denmark’s Economy, Sparking Economic and Policy Debates
Novo Nordisk, a Danish firm initially known for producing diabetes drugs, has become highly influential on Denmark's economy due to the remarkable success of its two obesity drugs, Ozempic and Wegovy. Their overseas sales surge led to lower interest rates in the country and contributed significantly […]
Mallinckrodt Files for Second Bankruptcy; Plans $1 Billion Debt Reduction Amid Opioid Litigation
Drugmaker Mallinckrodt has filed for its second bankruptcy in the US within three years, with a restructuring plan aiming to alleviate $1 billion from its owed amount to victims of the opioid crisis. The firm began Chapter 11 proceedings following an agreement that would hand the company over to its […]
UK Economy Showing Signs of Growth Despite Skills Shortage and Employment Challenges in the Biosciences Industry
The UK economy appears to avoid a possible recession and even shows signs of growth, according to the latest data from the Office for National Statistics (ONS). However, concerns persist about a challenging employment scenario in the biosciences industry due to a digital and data skills shortage in […]
Strategic Planning, Partnerships, and Compliance in Conflict Zones
Here's What You Need to Know: The PwC 25th Annual Global CEO Survey showed that geopolitical conflicts significantly threaten global growth, with 71% of CEOs saying they could inhibit business operations. Such conflicts can cause operating challenges for companies, particularly those […]
Potential and Challenges of Blockchain Technology in Healthcare
Blockchain, a distributed ledger technology known for supporting cryptocurrencies, has garnered interest in the healthcare sector due to its ability to securely and transparently share data. Its use in healthcare includes improving health information exchange, managing medical records, and tracking […]
Cost and Accessibility Concerns Over Lecanemab
The first drug aiming to slow the progression of Alzheimer's, lecanemab (brand name Leqembi), could cost the U.S. health care system billions annually and may not be accessible to many lower-income seniors who are most likely to suffer from dementia. While the drug costs $26,500 annually, treatment […]
Medicare Drug Price Negotiations Predicted to Yield $1.8 Billion Savings by 2026
A new report asserts that the Inflation Reduction Act will enforce a minimum discount that surpasses the 2020 rebates for only 4 out of 10 negotiated Medicare drugs by 2026. The four drugs, Enbrel, Imbruvica, Ibrance, and Xtandi, will be subject to minimum discounts of 60% and 25%, respectively. The […]
Proposing a Revolution in American Healthcare: Universal Basic Health Coverage
MIT Professors Amy Finkelstein and Liran Einav have proposed a total overhaul of the U.S. health insurance system, advocating for universal basic health coverage, in their book "We’ve Got You Covered: Rebooting American Health Care". The authors argue that the current patchwork of health policies […]
Economists Suggest That Universal Coverage Is Already Possible for the US: What Obstacles Still Stand in the Way?
The current state of health insurance in the U.S. needs to be revised, even for insured Americans who face the risk of massive medical bills for their covered care. The coverage is unstable, and the Affordable Care Act did relatively little to reduce the risk of insurance loss among those insured. […]
FDA Approves AstraZeneca’s Beyfortus
The Food and Drug Administration has approved an AstraZeneca-developed monoclonal antibody, Beyfortus, in an effort to protect infants and young children from severe illness caused by RSV, the number 1 cause of infant hospitalizations in the U.S. Beyfortus is expected to be recommended by the […]
BioGeneration Ventures Finalizes $167M Fund for Biotech Startups in Europe
What You Need To Know: Dutch venture capital firm BioGeneration Ventures (BGV) has secured €150 million ($167 million) for its fifth fund. The firm bases itself in Naarden, Netherlands, focusing on European drug developers. However, 78% of the new investors, forming most of the new investor […]
Insights into the Global Real World Evidence Solutions Market 2023-2030
10 Things You Need to Know: The projection shows the market size growing from $16.3 billion in 2023 to $36.24 billion in 2030, with a CAGR of 12.3%. IQVIA Inc., UnitedHealth Group, IBM, and Cognizant are currently the major players to pay attention to in the market. Advanced analytics […]
Meet inVentiv Health experts at DIA
We are a global provider of best-in-class clinical development and comprehensive commercialization services to the biopharmaceutical industry. Visit us at the event: booth #1517. […]
Health Care Cost, Quality and Outcomes: ISPOR Book of Terms
This ISPOR publication includes over 100 monographs covering over 400 terms used in health care delivery, management, and regulation, as well as health care outcomes research including clinical, economic, and quality-of-life research terms. Publication available here. […]
Therapeutic and Diagnostic Device Outcomes Research
This book informs: health outcomes researchers on the unique characteristics of therapeutic and diagnostic devices; medical device developers and researchers on the basic principles of clinical, economic; and patient-reported outcomes research for therapeutic and diagnostic […]
ISPOR Taxonomy of Patient Registries: Classification, Characteristics and Terms
This taxonomy describes the characteristics & classifications of patient registries and terms used in the design, development, implementation of registries, as well as the terms used in the analysis, reporting, and publishing of registry data. Each term includes a brief definition, a broader […]
Reliability and Validity of Data Sources for Outcomes Research & Disease and Health Management Programs
The ISPOR Health and Disease Management Special Interest Group developed this handbook as resource to improve the evidence base in health care studies with the ultimate goal of better patient outcomes and lower health care costs. This handbook provides an overview of the sources of data for […]
The Costs of Specialised Care
Chris Bojke, Katja Grasic, Andrew Street Patients requiring specialised care are usually treated by specialist teams with particular expertise and equipment. Concentrating services in this way should be cost-effective but there is concern that national tariffs might fail to fully reflect […]
Use of Multi-Criteria Decision Analysis (MCDA) in Health Care Decisions
Read more here. […]
